F Mavilio
Overview
Explore the profile of F Mavilio including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mavilio F
Gene Ther
. 2017 May;
24(9):590-592.
PMID: 28485723
For the last 20 years, academic research has been the major, and often only, driving force behind the spectacular development of gene transfer technology for the therapy of rare genetic...
2.
Cavazza A, Cocchiarella F, Bartholomae C, Schmidt M, Pincelli C, Larcher F, et al.
Gene Ther
. 2013 Apr;
20(9):949-57.
PMID: 23615186
Transplantation of epithelia derived from keratinocyte stem cells transduced by retroviral vectors is a potential therapy for epidermolysis bullosa (EB), a family of inherited skin adhesion defects. The biosafety characteristics...
3.
Almarza D, Bussadori G, Navarro M, Mavilio F, Larcher F, Murillas R
Gene Ther
. 2011 Mar;
18(7):674-81.
PMID: 21368897
Cutaneous gene therapy can be envisioned through the use of keratinocyte stem cell clones in which retroviral genotoxic risks can be pre-assessed. While transactivation of cellular genes by the retroviral...
4.
De Luca M, Pellegrini G, Mavilio F
Br J Dermatol
. 2009 May;
161(1):19-24.
PMID: 19466960
Gene therapy has the potential to treat devastating inherited diseases for which there is little hope of finding a conventional cure. These include lethal diseases, like immunodeficiencies or several metabolic...
5.
Pellegrini G, Rama P, Mavilio F, De Luca M
J Pathol
. 2008 Oct;
217(2):217-28.
PMID: 18855878
Regenerative medicine refers to innovative therapies aimed at the permanent restoration of diseased tissues and organs. Regeneration of self-renewing tissues requires specific adult stem cells, which need to be genetically...
6.
Butti E, Bergami A, Recchia A, Brambilla E, Del Carro U, Amadio S, et al.
Gene Ther
. 2008 Feb;
15(7):504-15.
PMID: 18239607
Central nervous system (CNS) delivery of anti-inflammatory cytokines, such as interleukin 4 (IL4), holds promise as treatment for multiple sclerosis (MS). We have previously shown that short-term herpes simplex virus...
7.
Butti E, Bergami A, Recchia A, Brambilla E, Franciotta D, Cattalini A, et al.
Gene Ther
. 2007 Oct;
15(3):233-8.
PMID: 17960158
Inflammation and immune reaction, or pre-existing immunity towards commonly used viral vectors for gene therapy severely impair long-term gene expression in the central nervous system (CNS), impeding the possibility to...
8.
Di Nunzio F, Piovani B, Cosset F, Mavilio F, Stornaiuolo A
Hum Gene Ther
. 2007 Sep;
18(9):811-20.
PMID: 17824830
Lentiviral vectors are efficiently pseudotyped with RD114-TR, a chimeric envelope glycoprotein made of the extracellular and transmembrane domains of the feline leukemia virus RD114 and the cytoplasmic tail of the...
9.
Bonini C, Grez M, Traversari C, Ciceri F, Marktel S, Ferrari G, et al.
Nat Med
. 2003 Apr;
9(4):367-9.
PMID: 12669036
No abstract available.
10.
Moreau-Gaudry F, Xia P, Jiang G, Perelman N, Bauer G, Ellis J, et al.
Blood
. 2001 Oct;
98(9):2664-72.
PMID: 11675336
Use of oncoretroviral vectors in gene therapy for hemoglobinopathies has been impeded by low titer vectors, genetic instability, and poor expression. Fifteen self- inactivating (SIN) lentiviral vectors using 4 erythroid...